HQY NASDAQ
HealthEquity, Inc.
1W: +11.5%
1M: +17.6%
3M: +2.5%
YTD: +13.9%
1Y: +7.7%
3Y: +36.3%
5Y: +63.0%
$101.33
-2.42 (-2.33%)
Weekly Expected Move ±3.5%
$97
$100
$104
$108
$111
Credit Risk of going bust: lower than 76% of companies Debt: 10.2% of company value Bonds: $84.1M held by 111 funds, 119 bp over Treasuries → details ▾
Of US companies ranked in the safest four tenths, about 1 in 3,500 filed for bankruptcy within a year (2020-2025).
If the stock fell to about $0.88 (down 99.2%), HealthEquity, Inc. would be worth roughly what it owes.
Total debt $971.0M against a stock market value of $8.58B.
Distance to default 8.75 (Merton model): prices to 2026-10-26, balance sheet 2026-07-31, debt counted $475.5M (short-term plus half of long-term), stock volatility 35.3%; Altman Z'' 3.10. A ranking and a back-test, not a forecast.
Bond figures are fund-reported marks (SEC N-PORT) as of Jul 2026. How these are computed.
If the stock fell to about $0.88 (down 99.2%), HealthEquity, Inc. would be worth roughly what it owes.
Total debt $971.0M against a stock market value of $8.58B.
Distance to default 8.75 (Merton model): prices to 2026-10-26, balance sheet 2026-07-31, debt counted $475.5M (short-term plus half of long-term), stock volatility 35.3%; Altman Z'' 3.10. A ranking and a back-test, not a forecast.
Bond figures are fund-reported marks (SEC N-PORT) as of Jul 2026. How these are computed.
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
#6
of 118
Medical - Healthcare Information Services
Technical Signal Map
9 Bullish
0 Neutral
4 Bearish
HQY
$8.6B
HealthEquity, Inc.
BULLISH
+91
PMCUF
$13B
Pro Medicus Limited
BULLISH
+91
HNGE
$9.0B
Hinge Health, Inc.
BULLISH
+91
DOCS
$6.0B
Doximity, Inc.
BULLISH
+91
WAY
$5.5B
Waystar Holding Corp.
BULLISH
+91
HTFL
$4.9B
Heartflow, Inc. Common Stock
BULLISH
+75
MTHRY
$8.2B
M3, Inc.
BULLISH
+58
PRVA
$2.9B
Privia Health Group, Inc.
BULLISH
+53
ALBHF
$6.3B
Alibaba Health Information Technology Limited
LEAN BULL
+11
BTSG
$12B
BrightSpring Health Services, Inc. Common Stock
LEAN BEAR
-11
BTSGU
$12B
BrightSpring Health Services, Inc. Tangible Equity Unit
LEAN BEAR
-27
PANHF
$2.1B
Ping An Healthcare and Technology Company Limited
BEARISH
-35
TEM
$12B
Tempus AI, Inc.
BEARISH
-75
Peer Comparison
| Symbol | Mkt Cap | P/E | ROE % | ROIC % | Net Mgn % | Rev Grw % | Piotroski | Signal | 1Y Ret % |
|---|---|---|---|---|---|---|---|---|---|
| HQY HealthEquity, Inc. | $8.6B | 36.6 | 11.4 | 9.9 | 18.7 | 7.3 | 8 | BULLISH | 7.7 |
| PMCUF Pro Medicus Limited | $13B | 78.1 | 75.0 | 68.1 | 68.7 | 22.8 | 7 | BULLISH | -30.9 |
| HNGE Hinge Health, Inc. | $9.0B | 82.6 | 30.4 | -235.0 | 20.5 | 417.7 | 7 | BULLISH | 125.4 |
| DOCS Doximity, Inc. | $6.0B | 36.5 | 17.2 | 60.2 | 15.5 | 11.2 | 6 | BULLISH | -50.1 |
| WAY Waystar Holding Corp. | $5.5B | 39.3 | 3.8 | 3.8 | 12.8 | 19.2 | 7 | BULLISH | -24.6 |
| HTFL Heartflow, Inc. Common Stock | $4.9B | -40.4 | -42.3 | -39.8 | -24.6 | — | 2 | BULLISH | 42.9 |
| MTHRY M3, Inc. | $8.2B | 27.5 | 12.1 | 16.9 | 10.1 | 17.7 | 7 | BULLISH | -16.9 |
| PRVA Privia Health Group, Inc. | $2.9B | 97.6 | 0.0 | 0.0 | 1.4 | 24.1 | 1 | BULLISH | -14.4 |
| ALBHF Alibaba Health Information Technology Limited | $6.3B | 19.9 | 11.2 | 20.8 | 3.8 | -36.2 | 3 | LEAN BULL | -50.2 |
| BTSG BrightSpring Health Services, Inc. Common Stock | $12B | 41.0 | 15.5 | 10.3 | 2.2 | 19.9 | 7 | LEAN BEAR | 75.8 |
| BTSGU BrightSpring Health Services, Inc. Tangible Equity Unit | $12B | 41.0 | 15.5 | 10.3 | 2.2 | 19.9 | 7 | LEAN BEAR | 70.4 |
| PANHF Ping An Healthcare and Technology Company Limited | $2.1B | 20.7 | 4.6 | 5.6 | 8.8 | 2.9 | 6 | BEARISH | -61.7 |
| TEM Tempus AI, Inc. | $12B | -48.0 | -67.4 | -19.8 | 1.5 | 50.4 | 4 | BEARISH | -22.8 |
| HQY HealthEquity, Inc. | $8.6B | 36.6 | 11.4 | 9.9 | 18.7 | 7.3 | 8 | BULLISH | 7.7 |
| CAI Caris Life Sciences, Inc. | $9.1B | 86.9 | 20.1 | 61.1 | -0.2 | 445.5 | 7 | BULLISH | 2.5 |
| KYMR Kymera Therapeutics, Inc. | $9.1B | -35.6 | -24.2 | -30.7 | -94.2 | 134.8 | 6 | BULLISH | 98.8 |
| ATR AptarGroup, Inc. | $8.1B | 22.6 | 13.6 | 10.1 | 8.5 | 8.9 | 6 | BULLISH | -2.8 |
| ESAIY Eisai Co., Ltd. | $9.2B | 34.0 | 3.8 | 3.3 | 7.8 | 248.0 | 6 | BULLISH | 9.2 |
| SYRE Spyre Therapeutics, Inc. | $8.3B | -48.2 | -23.0 | 359.8 | — | — | 3 | BULLISH | 315.3 |
| TGTX TG Therapeutics, Inc. | $8.3B | 18.1 | 100.3 | 73.5 | 3.2 | 76.1 | 6 | LEAN BULL | 63.6 |
| OSCR Oscar Health, Inc. | $8.0B | 18.4 | 34.3 | -9.6 | 7.4 | 42.8 | 7 | LEAN BULL | 58.5 |
| BRKR Bruker Corporation | $8.8B | -83.6 | -3.4 | 3.0 | -6.2 | 1.6 | 6 | NEUTRAL | 46.8 |
| KYKOF Kyowa Kirin Co., Ltd. | $8.1B | 15.6 | 9.3 | 14.2 | 12.8 | 7.4 | 7 | NEUTRAL | -8.1 |
| PTGX Protagonist Therapeutics, Inc. | $9.0B | 115.7 | 11.0 | 84.1 | 76.3 | 34.8 | 7 | NEUTRAL | 89.7 |
| HSIC Henry Schein, Inc. | $9.5B | 24.3 | 12.2 | 8.7 | 2.7 | 6.5 | 7 | BEARISH | 32.9 |
| PCVX Vaxcyte, Inc. | $9.5B | -7.9 | -36.5 | -66.4 | — | — | 0 | BEARISH | 44.2 |
| TWST Twist Bioscience Corporation | $9.2B | -69.7 | -29.6 | -29.2 | -29.6 | 19.2 | 2 | BEARISH | 356.3 |
| RMYHY Ramsay Health Care Limited | $9.2B | 40.8 | 6.6 | 4.2 | 1.8 | 4.2 | 7 | BEARISH | 85.2 |
| ARWR Arrowhead Pharmaceuticals, Inc. | $8.2B | -26.2 | -64.8 | 65.7 | -258.2 | 12.2 | 4 | BEARISH | 57.9 |
| TXG 10x Genomics, Inc. | $9.3B | -129.7 | -9.4 | -19.8 | -11.9 | -4.3 | 5 | BEARISH | 446.1 |
| CYTK Cytokinetics, Incorporated | $8.5B | -8.5 | 329.8 | 811.2 | -622.8 | -17.2 | 2 | BEARISH | 5.6 |
| KRYS Krystal Biotech, Inc. | $9.2B | 38.2 | 20.1 | 40.4 | 45.9 | 22.6 | 7 | BEARISH | 68.2 |
| CORT Corcept Therapeutics Incorporated | $9.3B | 166.5 | 8.1 | 3.1 | 16.5 | 16.0 | 6 | BEARISH | 19.4 |
| IBRX ImmunityBio, Inc. | $8.7B | -8.5 | 122.7 | 33.7 | -449.6 | 192.9 | 4 | BEARISH | 226.8 |
| HQY HealthEquity, Inc. | $8.6B | 36.6 | 11.4 | 9.9 | 18.7 | 7.3 | 8 | BULLISH | 7.7 |
| MDT Medtronic Plc | $122B | 23.0 | 10.7 | 7.8 | 15.1 | 9.8 | 9 | BULLISH | 4.0 |
| LZAGY Lonza Group AG | $54B | -409.1 | 13.5 | 10.5 | 17.5 | -9.7 | 8 | BULLISH | 6.2 |
| ORINY Orion Oyj | $30B | 23.1 | 53.6 | 46.3 | 26.9 | 22.6 | 7 | BULLISH | 46.8 |
| RPRX Royalty Pharma plc | $28B | 26.9 | 12.4 | 10.6 | 2.7 | 10.0 | 6 | BULLISH | 76.7 |
| LH Labcorp Holdings Inc. | $27B | 26.9 | 11.7 | 8.6 | 8.0 | 6.4 | 8 | BULLISH | 17.4 |
| ZBH Zimmer Biomet Holdings, Inc. | $19B | 23.2 | 6.4 | 5.9 | 9.1 | 8.6 | 6 | BULLISH | -5.5 |
| MEDP Medpace Holdings, Inc. | $19B | 36.7 | 117.9 | 1953.7 | 19.2 | 20.4 | 9 | BULLISH | 13.4 |
| CRL Charles River Laboratories International, Inc. | $17B | -73.3 | -7.7 | 6.9 | -0.1 | -0.7 | 4 | BULLISH | 87.0 |
| HALO Halozyme Therapeutics, Inc. | $14B | 36.0 | 173.7 | 32.5 | 47.8 | 41.2 | 5 | BULLISH | 91.4 |
| QGEN Qiagen N.V. | $10B | 25.8 | 11.9 | 11.2 | 19.3 | 3.0 | 8 | BULLISH | 2.1 |
| CAI Caris Life Sciences, Inc. | $9.1B | 86.9 | 20.1 | 61.1 | -0.2 | 445.5 | 7 | BULLISH | 2.5 |
| RGEDF Chemical Works of Gedeon Richter Plc | $7.4B | 10.6 | 16.2 | 24.3 | 15.9 | 1.8 | 5 | BULLISH | 33.2 |
| ALKS Alkermes plc | $7.3B | 109.6 | 3.9 | 2.9 | 0.1 | 10.8 | 4 | BULLISH | 47.9 |
| AMRX Amneal Pharmaceuticals, Inc. | $6.5B | 42.7 | -395.8 | 16.0 | 7.2 | 9.3 | 8 | BULLISH | 101.7 |
| MANE Veradermics, Incorporated | $5.8B | — | — | — | — | — | — | BULLISH | — |
| TFX Teleflex Incorporated | $5.8B | -5.8 | -28.8 | 1.3 | 17.9 | -14.5 | 5 | BULLISH | 3.8 |
| MMSI Merit Medical Systems, Inc. | $5.6B | 38.2 | 9.2 | 7.3 | 9.3 | 10.2 | 9 | BULLISH | 13.0 |
| CON Concentra Group Holdings Parent, Inc. | $5.0B | 25.7 | 48.5 | 66.4 | 10.8 | 14.0 | 9 | BULLISH | 96.2 |
| LFST LifeStance Health Group, Inc. | $4.9B | 100.0 | 3.4 | 4.1 | 5.4 | 20.4 | 7 | BULLISH | 154.1 |
| ATRC AtriCure, Inc. | $3.0B | 285.0 | 2.2 | 2.9 | 5.8 | 13.9 | 8 | BULLISH | 63.4 |
| GNNDY GN Store Nord A/S | $2.4B | -29.6 | -5.4 | 1.6 | -1.0 | -25.4 | 4 | BULLISH | -7.2 |
| VCEL Vericel Corporation | $2.2B | 89.8 | 7.2 | 5.9 | 2.8 | 23.0 | 7 | BULLISH | 19.6 |
| LKFT Lakefront Biotherapeutics N.V. | $2.1B | — | — | — | — | — | — | BULLISH | — |
| PFE Pfizer Inc. | $171B | 39.3 | 5.0 | 11.3 | -1.6 | -0.2 | 7 | BULLISH | 22.9 |
| DHR Danaher Corporation | $162B | 37.9 | 8.3 | 6.3 | 18.8 | 5.5 | 7 | BULLISH | 5.4 |
| CVS CVS Health Corp. | $120B | 24.2 | 6.2 | 4.9 | 2.8 | 7.4 | 8 | BULLISH | 14.1 |
| MCK McKesson Corporation | $117B | 26.2 | -148.0 | 237.7 | 0.6 | 8.8 | 8 | BULLISH | 25.3 |
| ELV Elevance Health Inc. | $95B | 18.2 | 11.6 | 16.2 | 2.7 | 3.6 | 7 | BULLISH | 25.2 |
| REGN Regeneron Pharmaceuticals, Inc. | $83B | 19.4 | 14.0 | 12.9 | 30.2 | 9.3 | 7 | BULLISH | 40.5 |
| CI Cigna Corporation | $81B | 12.5 | 15.5 | 11.8 | 2.3 | 7.7 | 8 | BULLISH | 0.9 |
| TKPHF Takeda Pharmaceutical Company Limited | $66B | 56.1 | 2.5 | 2.8 | 9.3 | 3.3 | 6 | BULLISH | 41.9 |
| CAH Cardinal Health, Inc. | $58B | 34.3 | -60.5 | 92.8 | 0.6 | 14.2 | 8 | BULLISH | 59.6 |
| BDX Becton, Dickinson and Company | $54B | 58.7 | 3.8 | 4.1 | 7.6 | -2.6 | 6 | BULLISH | 5.9 |
| SDZNY Sandoz Group AG | $42B | 66.7 | 7.2 | 10.1 | 1.9 | 29.1 | 6 | BULLISH | 60.0 |
| OTSKY Otsuka Holdings Co., Ltd. | $42B | 16.0 | 13.8 | 12.2 | 16.7 | 10.9 | 8 | BULLISH | 45.1 |
| ONC BeOne Medicines AG | $40B | 25.2 | 14.7 | 57.2 | 13.9 | 34.3 | 8 | BULLISH | 19.6 |
| CNC Centene Corp. | $35B | 23.8 | 6.8 | 6.4 | -0.1 | 4.8 | 8 | BULLISH | 98.1 |
| MTD Mettler-Toledo International Inc. | $33B | 37.5 | -736.4 | 46.7 | 22.7 | 6.9 | 8 | BULLISH | 16.2 |
| WST West Pharmaceutical Services, Inc. | $28B | 50.0 | 19.1 | 19.0 | 17.7 | 12.4 | 9 | BULLISH | 28.6 |
| EXEL Exelixis, Inc. | $16B | 19.7 | 44.4 | 69.0 | 33.7 | 9.2 | 8 | BULLISH | 71.1 |
| ICLR ICON Public Limited Company | $14B | 42.7 | 3.5 | 5.5 | 3.5 | 2.0 | 6 | BULLISH | 2.1 |
| PMCUF Pro Medicus Limited | $13B | 78.1 | 75.0 | 68.1 | 68.7 | 22.8 | 7 | BULLISH | -30.9 |
| AVTR Avantor, Inc. | $12B | -20.5 | -9.7 | -2.5 | 2.3 | -1.6 | 6 | BULLISH | 11.8 |
| GKOS Glaukos Corporation | $11B | -56.6 | -26.0 | -12.7 | -9.9 | 41.5 | 3 | BULLISH | 137.1 |
| HNGE Hinge Health, Inc. | $9.0B | 82.6 | 30.4 | -235.0 | 20.5 | 417.7 | 7 | BULLISH | 125.4 |
| PACS PACS Group, Inc. | $7.5B | 27.9 | 28.1 | 6.9 | 5.3 | 15.2 | 8 | BULLISH | 282.6 |
| SSMXY Sysmex Corporation | $7.4B | 30.7 | 8.5 | 10.0 | 6.7 | 6.2 | 5 | BULLISH | 4.1 |
| DOCS Doximity, Inc. | $6.0B | 36.5 | 17.2 | 60.2 | 15.5 | 11.2 | 6 | BULLISH | -50.1 |
| WAY Waystar Holding Corp. | $5.5B | 39.3 | 3.8 | 3.8 | 12.8 | 19.2 | 7 | BULLISH | -24.6 |
| HKMPY Hikma Pharmaceuticals PLC | $4.6B | 12.6 | 15.3 | 12.1 | 12.9 | 6.1 | 7 | BULLISH | -3.4 |
| ARQT Arcutis Biotherapeutics, Inc. | $3.9B | 144.7 | 15.9 | 34.7 | 11.6 | 76.1 | 7 | BULLISH | 58.4 |
| ACHC Acadia Healthcare Company, Inc. | $2.9B | -2.5 | -44.5 | 6.1 | 1.3 | 4.3 | 4 | BULLISH | 33.4 |
| BVNRY Bavarian Nordic A/S | $2.9B | 12.9 | 12.3 | 7.1 | 36.0 | -5.8 | 7 | BULLISH | -0.2 |
| BHC Bausch Health Companies Inc. | $2.4B | -2.1 | 86.8 | 12.2 | 9.0 | 10.5 | 5 | BULLISH | -0.3 |
| MD Pediatrix Medical Group, Inc. | $2.4B | 13.6 | 20.4 | 15.9 | 8.2 | 0.5 | 7 | BULLISH | 69.1 |
| FTRE Fortrea Holdings Inc. | $2.2B | -25.6 | -15.3 | 0.6 | -1.9 | -2.1 | 6 | BULLISH | 120.7 |
| PGNY Progyny, Inc. | $2.2B | 28.9 | 16.2 | 30.2 | 8.0 | 5.5 | 7 | BULLISH | 44.3 |
| PRGO Perrigo Company plc | $2.2B | -1.2 | -49.6 | 3.1 | 7.3 | -4.2 | 4 | BULLISH | -24.8 |
| AGIO Agios Pharmaceuticals, Inc. | $2.2B | -5.2 | -34.3 | -82.5 | -225.1 | 140.6 | 4 | BULLISH | -12.4 |
| BOEUF Bonesupport Holding AB (publ) | $2.1B | 79.5 | 29.2 | 54.1 | 22.6 | 23.4 | 8 | BULLISH | 36.7 |
| HCA HCA Healthcare, Inc. | $102B | 54.8 | -124.7 | 23.3 | 8.4 | 7.3 | 6 | BULLISH | 5.7 |
| IDXX IDEXX Laboratories, Inc. | $44B | 39.5 | 74.2 | 46.5 | 27.8 | 12.8 | 9 | BULLISH | -10.7 |
| GEHC GE HealthCare Technologies Inc. | $32B | 20.2 | 15.4 | 10.6 | 10.8 | 1.4 | 5 | BULLISH | -6.8 |
| CLPBY Coloplast A/S | $17B | 38.5 | 18.5 | 70.9 | 19.9 | -2.9 | 5 | BULLISH | -21.7 |
| ASND Ascendis Pharma A/S | $15B | 18.1 | 121.1 | 76.2 | 61.0 | 114.8 | 7 | BULLISH | 22.0 |
| PEN Penumbra, Inc. | $13B | 79.4 | 11.4 | 13.6 | 8.9 | 17.6 | 6 | BULLISH | 28.3 |
| SGRY Surgery Partners, Inc. | $2.1B | -33.7 | -5.2 | 5.9 | -1.8 | 4.0 | 5 | BULLISH | 5.8 |
| ABT Abbott Laboratories | $179B | 38.3 | 10.7 | 7.3 | 7.4 | 8.1 | 5 | BULLISH | -17.0 |
| ISRG Intuitive Surgical, Inc. | $160B | 53.8 | 18.0 | 22.6 | 17.1 | 20.5 | 7 | BULLISH | -18.1 |
| SYK Stryker Corporation | $118B | 30.8 | 16.5 | 11.6 | 19.4 | 8.5 | 9 | BULLISH | -20.0 |
| SNY Sanofi | $100B | 23.0 | 5.7 | 6.4 | 2.8 | 13.4 | 6 | BULLISH | -15.6 |
| CHGCF Chugai Pharmaceutical Co., Ltd. | $74B | 23.3 | 23.7 | 45.1 | 34.1 | 12.6 | 6 | BULLISH | 1.2 |
| BSX Boston Scientific Corporation | $66B | 18.1 | 15.5 | 11.6 | 16.7 | 13.5 | 8 | BULLISH | -55.5 |
| UTHR United Therapeutics Corporation | $25B | 19.3 | 19.3 | 31.3 | 42.5 | 2.5 | 6 | BULLISH | 39.1 |
| PODD Insulet Corp. | $10B | 27.6 | 26.0 | 21.3 | 11.8 | 29.4 | 9 | BULLISH | -53.9 |
| BLCO Bausch + Lomb Corporation | $6.2B | -37.0 | -2.7 | 2.8 | -1.0 | 8.8 | 5 | BULLISH | 11.2 |
| IRTC iRhythm Technologies, Inc. | $4.0B | -281.8 | -9.6 | -3.4 | -0.2 | 25.6 | 6 | BULLISH | -33.1 |
| LEGN Legend Biotech Corporation | $3.6B | -41.1 | -8.1 | -8.2 | 8.6 | 59.5 | 4 | BULLISH | -35.6 |
| WILYY Demant A/S | $12B | 46.7 | 15.9 | 10.9 | 9.1 | 10.6 | 5 | BULLISH | 47.3 |
| HLN Haleon plc | $45B | 20.7 | 10.1 | 8.4 | 13.6 | 1.3 | 8 | BULLISH | 8.9 |
| ZTS Zoetis Inc. | $33B | 13.0 | 64.4 | 26.3 | 28.0 | 1.4 | 6 | BULLISH | -44.5 |
| PHG Koninklijke Philips N.V. | $26B | 20.3 | 10.2 | 7.6 | 8.8 | -1.1 | 6 | BULLISH | -8.4 |
| SNN Smith & Nephew plc | $13B | 19.8 | 11.8 | 9.9 | 9.8 | 5.3 | 7 | BULLISH | -14.2 |
| COO The Cooper Companies, Inc. | $12B | 20.4 | 6.8 | 6.3 | 40.6 | 4.7 | 6 | BULLISH | -17.9 |
| VRDN Viridian Therapeutics, Inc. | $2.5B | -6.6 | -65.7 | 418.2 | -44760.2 | 23220.3 | 4 | BULLISH | 5.8 |
| ESLOF EssilorLuxottica S.A. | $94B | 33.2 | 6.5 | 5.2 | 10.6 | 7.4 | 6 | BULLISH | -44.7 |
| SOAGY Sartorius AG ADR | $92B | 90.9 | 7.7 | 6.6 | 7.1 | 4.3 | 7 | BULLISH | 18.0 |
| EW Edwards Lifesciences Corporation | $51B | 51.7 | 9.5 | 17.9 | 13.9 | 14.6 | 6 | BULLISH | 18.3 |
| BIIB Biogen Inc. | $37B | 44.2 | 4.6 | 4.8 | 3.6 | -0.5 | 3 | BULLISH | 68.1 |
| TRUMY Terumo Corporation | $22B | 21.5 | 11.0 | 9.6 | 22.6 | 15.6 | 5 | BULLISH | -8.5 |
| ALGN Align Technology, Inc. | $11B | 26.3 | 10.2 | 12.3 | 10.3 | 4.4 | 7 | BULLISH | 12.0 |
| HTFL Heartflow, Inc. Common Stock | $4.9B | -40.4 | -42.3 | -39.8 | -24.6 | — | 2 | BULLISH | 42.9 |
| DSRLF DiaSorin S.p.A. | $4.4B | 25.0 | 14.2 | 8.9 | 14.0 | 46.3 | 5 | BULLISH | -2.4 |
| VCYT Veracyte, Inc. | $3.9B | 33.6 | 8.8 | 10.7 | 17.0 | 17.3 | 8 | BULLISH | 35.2 |
| PLSE Pulse Biosciences, Inc. | $3.8B | -45.2 | -78.5 | -1410.2 | -5681.3 | — | 3 | BULLISH | 202.6 |
| CZMWY Carl Zeiss Meditec AG | $3.5B | 21.2 | 5.6 | 4.8 | 9.8 | 22.1 | 7 | BULLISH | -28.0 |
| AVAH Aveanna Healthcare Holdings Inc. | $2.9B | 9.8 | 199.1 | 30.4 | 6.0 | 20.3 | 6 | BULLISH | 44.5 |
| SZUKF Suzuken Co., Ltd. | $2.4B | 10.9 | 9.3 | 8.6 | 0.5 | 5.0 | 4 | BULLISH | 18.9 |
| AUPH Aurinia Pharmaceuticals Inc. | $2.2B | 7.2 | 66.1 | 127.2 | 45.0 | 19.8 | 7 | BULLISH | 47.1 |
| BHVN Biohaven Ltd. | $2.1B | -3.1 | -799.5 | -1083.0 | — | — | 3 | BULLISH | -11.3 |
| NTRA Natera, Inc. | $58B | -297.1 | -12.5 | -23.6 | -8.9 | 37.8 | 6 | BULLISH | 107.6 |
| MKGAF Merck KGaA | $70B | 26.1 | 8.1 | 8.1 | 9.0 | -0.4 | 7 | BULLISH | 24.1 |
| COR Cencora, Inc. | $63B | 24.2 | 104.3 | 26.5 | 0.9 | 5.1 | 7 | BULLISH | 0.7 |
| IQV IQVIA Holdings Inc. | $46B | 33.0 | 21.7 | 33.3 | 7.9 | 8.8 | 9 | BULLISH | 24.4 |
| WAT Waters Corporation | $45B | 114.0 | 1.9 | 1.5 | -8.3 | 52.5 | 5 | BULLISH | 28.2 |
| GNMSF Genmab A/S | $28B | 34.9 | 3.9 | 11.9 | 26.2 | -82.1 | 4 | BULLISH | 50.6 |
| SONVF Sonova Holding AG | $20B | 38.9 | 20.4 | 17.2 | 19.7 | -7.1 | 6 | BULLISH | 22.9 |
| BAX Baxter International Inc. | $13B | -12.2 | -15.7 | -1.6 | 4.3 | 5.4 | 3 | BULLISH | 10.2 |
| GNGBY Getinge AB (publ) | $7.3B | 25.9 | 9.1 | 8.1 | 8.5 | -3.9 | 7 | BULLISH | 13.2 |
| HLUBF H. Lundbeck A/S | $7.3B | 13.4 | 15.2 | 12.6 | 17.6 | 10.1 | 7 | BULLISH | 22.5 |
| CNVVY ConvaTec Group Plc | $6.3B | 50.8 | 7.6 | 10.2 | 4.4 | 5.5 | 5 | BULLISH | -0.4 |
| MAHLY MediPal Holdings Corporation | $4.1B | 15.1 | 7.5 | 8.7 | 1.4 | 5.9 | 7 | BULLISH | 23.9 |
| IRON Disc Medicine, Inc. | $2.9B | -12.1 | -39.1 | 1672.3 | — | — | 1 | BULLISH | -7.2 |
| NRIX Nurix Therapeutics, Inc. | $2.8B | 10.2 | 44.0 | -1896.6 | 81.7 | 738.8 | 8 | BULLISH | 145.5 |
| ZYME Zymeworks Inc. | $2.0B | -14.0 | -72.3 | -156.9 | -980.8 | -69.8 | 2 | BULLISH | 63.0 |
| UCBJY UCB S.A. | $58B | 23.3 | 20.7 | 16.4 | 26.0 | 25.3 | 6 | BULLISH | 5.3 |
| ALC Alcon Inc. | $34B | 53.5 | 2.9 | 3.6 | 0.0 | 7.8 | 6 | BULLISH | -8.2 |
| STE STERIS plc | $23B | 27.9 | 11.4 | 9.7 | 13.4 | 8.4 | 8 | BULLISH | -4.6 |
| LVZPF Livzon Pharmaceutical Group Inc. | $6.1B | 16.0 | 11.5 | 16.4 | 15.3 | -14.4 | 4 | BULLISH | 0.0 |
| ORKA Oruka Therapeutics, Inc. | $5.3B | -37.6 | -18.2 | -50.3 | — | — | 4 | BULLISH | 232.9 |
| GSK GSK plc | $102B | 16.0 | 25.5 | 18.8 | 5.2 | 5.0 | 7 | BULLISH | 13.2 |
| SEMHF Siemens Healthineers AG | $53B | 21.2 | 12.1 | 8.4 | 11.6 | 10.0 | 9 | BULLISH | -17.7 |
| DGX Quest Diagnostics Incorporated | $27B | 23.6 | 15.2 | 10.2 | 10.1 | 9.1 | 8 | BULLISH | 32.6 |
| SAUHY Straumann Holding AG | $19B | 41.8 | 17.3 | 21.7 | 18.1 | 3.0 | 6 | BULLISH | 5.1 |
| NBIX Neurocrine Biosciences, Inc. | $15B | 20.6 | 22.1 | 16.0 | 15.1 | 34.4 | 6 | BULLISH | 1.5 |
| GMED Globus Medical, Inc. | $11B | 20.2 | 11.8 | 12.3 | 19.2 | 19.7 | 8 | BULLISH | 30.2 |
| KYMR Kymera Therapeutics, Inc. | $9.1B | -35.6 | -24.2 | -30.7 | -94.2 | 134.8 | 6 | BULLISH | 98.8 |
| OPHLY Ono Pharmaceutical Co., Ltd. | $7.4B | 15.2 | 9.5 | 11.3 | 20.8 | 3.3 | 9 | BULLISH | 32.7 |
| ERAS Erasca, Inc. | $5.0B | -15.7 | -78.2 | -87.5 | — | — | 2 | BULLISH | 578.3 |
| LIVN LivaNova PLC | $4.4B | 23.3 | 15.4 | 30.2 | 27.8 | 12.4 | 8 | BULLISH | 48.1 |
| SNPHY Santen Pharmaceutical Co., Ltd. | $3.6B | 14.7 | 13.6 | 14.9 | 10.4 | 0.9 | 8 | BULLISH | 10.7 |
| CSLLY CSL Limited | $134B | -26.2 | -15.2 | 13.1 | -40.2 | 1.7 | 4 | BULLISH | -1.5 |
| RVTY Revvity, Inc. | $18B | 76.0 | 3.2 | 3.5 | 7.1 | 5.5 | 6 | BULLISH | 64.4 |
| TECH Bio-Techne Corporation | $11B | 62.1 | 9.0 | 8.9 | 17.0 | -0.4 | 7 | BULLISH | 10.2 |
| MOH Molina Healthcare, Inc. | $11B | -329.7 | -1.2 | -44.2 | 0.4 | -2.1 | 5 | BULLISH | 27.3 |
| MTHRY M3, Inc. | $8.2B | 27.5 | 12.1 | 16.9 | 10.1 | 17.7 | 7 | BULLISH | -16.9 |
| HAE Haemonetics Corporation | $5.4B | 57.8 | 11.2 | 10.1 | 9.7 | 0.4 | 8 | BULLISH | 132.2 |
| CDNA CareDx, Inc | $3.6B | 32.7 | 29.5 | -2.5 | 83.8 | 34.4 | 8 | BULLISH | 370.1 |
| ONTTF Oxford Nanopore Technologies plc | $2.7B | -17.4 | -25.6 | -36.2 | -41.1 | 14.4 | 4 | BULLISH | 41.4 |
| ESAIY Eisai Co., Ltd. | $9.2B | 34.0 | 3.8 | 3.3 | 7.8 | 248.0 | 6 | BULLISH | 9.2 |
| ATR AptarGroup, Inc. | $8.1B | 22.6 | 13.6 | 10.1 | 8.5 | 8.9 | 6 | BULLISH | -2.8 |
| AKBLF ALK-Abelló A/S | $7.4B | 39.7 | 21.2 | 23.9 | 18.9 | 16.4 | 8 | BULLISH | 12.8 |
| OPCH Option Care Health, Inc. | $4.7B | 23.5 | 16.0 | 10.6 | 3.7 | 5.9 | 5 | BULLISH | 11.4 |
| AMBBY Ambu A/S | $3.2B | 41.7 | 8.5 | 9.0 | 9.5 | -411.9 | 6 | BULLISH | -28.5 |
| PRVA Privia Health Group, Inc. | $2.9B | 97.6 | 0.0 | 0.0 | 1.4 | 24.1 | 1 | BULLISH | -14.4 |
| ADMA ADMA Biologics, Inc. | $2.4B | 15.2 | 41.9 | 35.5 | 30.4 | 8.0 | 5 | BULLISH | -27.4 |
| DRWKF Drägerwerk AG & Co. KGaA | $2.3B | 11.1 | 11.0 | 9.8 | 3.5 | 6.5 | 9 | BULLISH | 36.8 |
| IPSEY Ipsen S.A. | $58B | 24.4 | 11.5 | 16.3 | 18.2 | 8.0 | 6 | BULLISH | 25.4 |
| GILD Gilead Sciences, Inc. | $193B | -60.6 | -20.6 | -3.4 | -134.5 | 5.5 | 5 | BULLISH | 32.3 |
| DSNKY Daiichi Sankyo Company, Limited | $33B | 19.6 | 15.1 | 12.5 | 11.9 | 17.4 | 5 | BULLISH | -33.2 |
| ROIV Roivant Sciences Ltd. | $26B | -95.0 | -6.2 | -217.5 | -13164.4 | -67.6 | 1 | BULLISH | 99.0 |
| VTRS Viatris Inc. | $21B | -51.7 | -2.8 | -0.3 | -3.2 | 4.4 | 7 | BULLISH | 79.5 |
| BMXXY bioMérieux S.A. | $12B | 22.6 | 11.2 | 8.9 | 11.5 | -3.5 | 7 | BULLISH | -28.0 |
| DVA DaVita Inc. | $12B | 15.7 | -149.4 | 17.9 | 7.5 | 6.4 | 8 | BULLISH | 43.8 |
| UHS Universal Health Services, Inc. | $11B | 7.2 | 21.0 | 12.5 | 7.7 | 10.0 | 8 | BULLISH | -10.8 |
| RDY Dr. Reddy's Laboratories Limited | $11B | 39.0 | 7.5 | 6.0 | 10.7 | -3.1 | 4 | BULLISH | -5.9 |
| HUM Humana Inc. | $51B | 39.2 | 6.8 | 17.2 | 1.7 | 18.3 | 4 | BULLISH | 43.1 |
| TCHBF Tecan Group AG | $3.5B | -26.4 | -9.7 | 2.8 | 2.9 | -4.2 | 6 | BULLISH | 45.2 |
| RCDTF Recordati Industria Chimica e Farmaceutica S.p.A. | $12B | 21.8 | 24.9 | 15.4 | 16.7 | 9.2 | 7 | BULLISH | -9.2 |
| GRAL GRAIL Inc. | $5.9B | -15.0 | -16.1 | -24.9 | -246.7 | 23.1 | 5 | BULLISH | 69.3 |
| EKTAY Elekta AB (publ) | $2.2B | -61.1 | -4.4 | -49.1 | 7.5 | -7.8 | 4 | BULLISH | 8.0 |
| FSNUY Fresenius SE & Co. KGaA | $117B | 16.8 | 8.1 | 5.6 | 6.4 | 5.9 | 7 | BULLISH | -18.2 |
| ENSG The Ensign Group, Inc. | $10B | 26.2 | 17.0 | 8.1 | 6.9 | 18.9 | 7 | BULLISH | -4.6 |
| BLLN BillionToOne, Inc. | $5.1B | 161.6 | 6.0 | 25.2 | 7.4 | — | 4 | BULLISH | — |
| THC Tenet Healthcare Corporation | $22B | 9.8 | 53.3 | 19.1 | 14.7 | 5.4 | 7 | BULLISH | 30.0 |
| SYRE Spyre Therapeutics, Inc. | $8.3B | -48.2 | -23.0 | 359.8 | — | — | 3 | BULLISH | 315.3 |
| ERFSF Eurofins Scientific SE | $17B | 28.5 | 12.8 | 4.6 | 8.2 | 3.3 | 6 | BULLISH | 33.0 |
| FSPKF Fisher & Paykel Healthcare Corporation Limited | $16B | 60.2 | 23.3 | 27.3 | 20.6 | 5.0 | 6 | BULLISH | 45.1 |
| ICUI ICU Medical, Inc. | $4.2B | 137.6 | 1.4 | 2.7 | 3.5 | -9.0 | 6 | BULLISH | 36.4 |
| ADUS Addus HomeCare Corporation | $2.3B | 21.3 | 9.7 | 9.6 | 7.3 | 15.9 | 6 | BULLISH | 0.4 |
| EHC Encompass Health Corporation | $12B | 19.5 | 25.5 | 16.7 | 9.6 | 9.5 | 9 | BULLISH | -1.8 |
| LQDA Liquidia Corporation | $3.8B | 28.2 | 131.8 | 391.9 | 43.5 | 2233.6 | 6 | BULLISH | 98.6 |
| VRTX Vertex Pharmaceuticals Incorporated | $133B | 29.7 | 23.5 | 28.3 | 33.0 | 10.6 | 6 | BULLISH | 22.4 |
| SGIOY Shionogi & Co., Ltd. | $16B | 9.8 | 13.6 | 9.9 | 50.6 | 10.3 | 5 | BULLISH | 20.9 |
| RGEN Repligen Corporation | $11B | -823.9 | -0.6 | -1.4 | -18.4 | 13.8 | 4 | BULLISH | 9.0 |
| CHEOY Cochlear Limited | $6.7B | 62.1 | 7.8 | 11.6 | -1.2 | -1.2 | 6 | BULLISH | -47.8 |
| CHE Chemed Corporation | $6.7B | 25.6 | 27.1 | 23.2 | 10.1 | 3.3 | 6 | BULLISH | 18.1 |
| LGND Ligand Pharmaceuticals Incorporated | $6.0B | 30.9 | 22.0 | 11.3 | 76.2 | 54.9 | 5 | BULLISH | 66.4 |
| APNHY Aspen Pharmacare Holdings Limited | $4.2B | 26.8 | 3.2 | 5.3 | 6.6 | -20.1 | 7 | BULLISH | 69.4 |
| ALPMF Astellas Pharma Inc. | $30B | 12.4 | 21.4 | 16.9 | 22.1 | 17.3 | 7 | BULLISH | 65.7 |
| HCM HUTCHMED (China) Limited | $2.6B | 149.4 | 46.6 | 11.0 | 5.7 | -11.8 | 6 | BULLISH | -5.1 |
| IOVA Iovance Biotherapeutics, Inc. | $6.4B | -19.3 | -40.4 | -49.1 | -47.6 | 34.5 | 6 | BULLISH | 529.2 |
| ILMN Illumina, Inc. | $41B | 51.2 | 32.4 | 18.2 | 17.9 | 4.9 | 7 | LEAN BULL | 171.1 |
| BBIO BridgeBio Pharma, Inc. | $13B | -19.2 | 32.4 | 57.9 | -62.5 | 202.4 | 4 | LEAN BULL | 26.6 |
| SHC Sotera Health Company | $5.2B | 32.1 | 27.8 | 10.6 | 16.7 | 8.1 | 7 | LEAN BULL | 8.8 |
| TGTX TG Therapeutics, Inc. | $8.3B | 18.1 | 100.3 | 73.5 | 3.2 | 76.1 | 6 | LEAN BULL | 63.6 |
| SHTDF Sinopharm Group Co. Ltd. | $6.3B | 6.2 | 8.4 | 8.1 | 1.2 | -2.2 | 5 | LEAN BULL | -18.8 |
| MRVI Maravai LifeSciences Holdings, Inc. | $2.1B | -14.2 | -32.9 | 24.4 | -24.1 | -3.3 | 5 | LEAN BULL | 117.8 |
| A Agilent Technologies, Inc. | $49B | 34.6 | 21.0 | 14.9 | 19.3 | 8.6 | 7 | LEAN BULL | 19.3 |
| SDGCF Sundrug Co.,Ltd. | $3.3B | 13.5 | 11.4 | 10.6 | 3.7 | 4.9 | 6 | LEAN BULL | 0.0 |
| ARHCF Alfresa Holdings Corporation | $2.5B | 11.4 | 5.7 | 7.8 | 0.2 | 3.6 | 5 | LEAN BULL | 17.9 |
| INSP Inspire Medical Systems, Inc. | $2.1B | 15.0 | 18.0 | 19.7 | 0.2 | 4.3 | 8 | LEAN BULL | -11.4 |
| OSCR Oscar Health, Inc. | $8.0B | 18.4 | 34.3 | -9.6 | 7.4 | 42.8 | 7 | LEAN BULL | 58.5 |
| HOCPY HOYA Corporation | $56B | 33.4 | 27.3 | 46.1 | 25.7 | 14.2 | 6 | LEAN BULL | 10.1 |
| BIO Bio-Rad Laboratories, Inc. | $9.9B | 45.0 | 3.1 | 2.2 | 57.1 | 1.4 | 7 | LEAN BULL | 10.1 |
| KOD Kodiak Sciences Inc. | $5.5B | -22.0 | -368.4 | -630.1 | — | — | 1 | LEAN BULL | 423.7 |
| NVST Envista Holdings Corp | $3.8B | 40.1 | 3.1 | 3.2 | 7.4 | 11.9 | 7 | LEAN BULL | 17.0 |
| BMY Bristol-Myers Squibb Company | $126B | 13.5 | 46.7 | 17.8 | 25.6 | 3.1 | 8 | LEAN BULL | 46.8 |
| TEVA Teva Pharmaceutical Industries Limited | $46B | 64.1 | 9.7 | 9.3 | -13.9 | 4.1 | 7 | LEAN BULL | 110.1 |
| BIOVF Swedish Orphan Biovitrum AB | $16B | 115.7 | 3.4 | 17.2 | 14.0 | 13.3 | 4 | LEAN BULL | 37.3 |
| PBH Prestige Consumer Healthcare Inc. | $2.3B | 13.0 | 9.1 | 5.5 | 11.0 | -1.4 | 4 | LEAN BULL | -23.0 |
| SKHHY Sonic Healthcare Limited | $6.5B | 15.5 | 7.3 | 6.2 | 6.2 | 52.7 | 5 | LEAN BULL | -6.3 |
| ALBHF Alibaba Health Information Technology Limited | $6.3B | 19.9 | 11.2 | 20.8 | 3.8 | -36.2 | 3 | LEAN BULL | -50.2 |
| GH Guardant Health, Inc. | $23B | -49.9 | 171.6 | -88.3 | -35.9 | 42.7 | 6 | LEAN BULL | 149.8 |
| NEOG Neogen Corporation | $2.7B | -49.4 | -2.7 | -0.2 | -5.3 | -0.3 | 7 | LEAN BULL | 101.2 |
| FMS Fresenius Medical Care AG & Co. KGaA | $12B | 12.2 | 7.3 | 6.7 | 4.5 | -0.5 | 7 | NEUTRAL | -15.4 |
| BRKR Bruker Corporation | $8.8B | -83.6 | -3.4 | 3.0 | -6.2 | 1.6 | 6 | NEUTRAL | 46.8 |
| MSMKF MatsukiyoCocokara & Co. | $5.8B | 18.0 | 11.1 | 12.6 | 5.1 | 5.7 | 8 | NEUTRAL | -16.3 |
| ZLAB Zai Lab Limited | $2.7B | -13.3 | -26.9 | -85.4 | -47.8 | 5.1 | 3 | NEUTRAL | -13.1 |
| KYKOF Kyowa Kirin Co., Ltd. | $8.1B | 15.6 | 9.3 | 14.2 | 12.8 | 7.4 | 7 | NEUTRAL | -8.1 |
| ITGR Integer Holdings Corporation | $4.3B | 34.3 | 7.5 | 5.4 | 5.1 | 2.6 | 7 | NEUTRAL | 71.3 |
| AAVXF Abivax S.A. | $12B | -16.7 | -221.8 | 440.6 | — | -133.5 | 4 | NEUTRAL | 57.0 |
| PTGX Protagonist Therapeutics, Inc. | $9.0B | 115.7 | 11.0 | 84.1 | 76.3 | 34.8 | 7 | NEUTRAL | 89.7 |
| BCHMF Bachem Holding AG | $6.8B | 41.6 | 10.6 | 8.2 | 15.4 | 4.3 | 3 | NEUTRAL | 24.7 |
| AHICF Asahi Intecc Co., Ltd. | $5.7B | 30.5 | 20.0 | 27.8 | 14.6 | 21.6 | 9 | NEUTRAL | 33.4 |
| BUHPF Bumrungrad Hospital Public Company Limited | $4.8B | 21.0 | 27.3 | 37.3 | 30.3 | 1.6 | 5 | NEUTRAL | 23.7 |
| ANSLY Ansell Limited | $4.7B | 22.3 | 10.6 | 9.5 | 10.8 | 7.1 | 8 | NEUTRAL | 43.8 |
| CSMYF COSMOS Pharmaceutical Corporation | $3.2B | 15.6 | 11.7 | 9.8 | 2.9 | 9.5 | 6 | NEUTRAL | -12.2 |
| JDHIY JD Health International Inc. | $16B | 16.4 | 10.3 | 31.0 | 8.4 | 19.6 | 6 | NEUTRAL | -43.9 |
| CHJTF CSPC Pharmaceutical Group Limited | $14B | 10.3 | 20.7 | 36.7 | 32.8 | 88.1 | 6 | NEUTRAL | 13.3 |
| TSUSF Tsuruha Holdings Inc. | $4.2B | 17.4 | 6.2 | 12.0 | 2.8 | 16.1 | 5 | NEUTRAL | 56.8 |
| NONOF Novo Nordisk A/S | $172B | 9.9 | 59.8 | 35.2 | 26.7 | 5.6 | 5 | NEUTRAL | -28.1 |
| IHHHF IHH Healthcare Berhad | $15B | 30.9 | 7.3 | 6.1 | 8.1 | 7.1 | 5 | NEUTRAL | 43.7 |
| DNPUF Sumitomo Pharma Co., Ltd. | $6.4B | 6.9 | 39.1 | 10.3 | 13.1 | 14.5 | 6 | NEUTRAL | 5.6 |
| SGFEF Siegfried Holding AG | $3.9B | 19.0 | 17.0 | 9.4 | 10.8 | 3.4 | 4 | NEUTRAL | -15.8 |
| AXGN AxoGen, Inc. | $2.2B | -55.9 | -18.2 | -5.6 | -2.2 | 23.6 | 4 | NEUTRAL | 110.6 |
| BTSG BrightSpring Health Services, Inc. Common Stock | $12B | 41.0 | 15.5 | 10.3 | 2.2 | 19.9 | 7 | LEAN BEAR | 75.8 |
| GEDSF Gedeon Richter PLC | $4.5B | 10.6 | 16.4 | 22.0 | 29.6 | 4.8 | 7 | LEAN BEAR | 0.0 |
| GLPGF Lakefront Biotherapeutics | $2.1B | 3.8 | 20.2 | 39.4 | 17.4 | 259.3 | 5 | LEAN BEAR | -4.5 |
| MRNA Moderna, Inc. | $80B | -23.4 | -39.0 | -90.1 | -539.3 | -27.2 | 2 | LEAN BEAR | 681.3 |
| RDNT RadNet, Inc. | $5.5B | -278.6 | -2.1 | 1.8 | 1.2 | 18.9 | 5 | LEAN BEAR | -15.5 |
| COGT Cogent Biosciences, Inc. | $5.4B | -13.5 | -109.7 | 1964.0 | — | — | 3 | LEAN BEAR | 108.3 |
| STVN Stevanato Group S.p.A. | $5.3B | 36.7 | 9.1 | 7.2 | 7.6 | 6.7 | 6 | LEAN BEAR | -28.0 |
| DFTX Definium Therapeutics, Inc. | $4.8B | -10.4 | -25.7 | 82.4 | — | — | 2 | LEAN BEAR | — |
| SUVPF Sartorius AG | $19B | 90.9 | 7.7 | 6.7 | 7.1 | 3.6 | 7 | LEAN BEAR | 8.9 |
| RLAY Relay Therapeutics, Inc. | $4.0B | -11.7 | -36.8 | -2519.7 | -23916.3 | 23.9 | 4 | LEAN BEAR | 168.1 |
| ALMR Alamar Biosciences, Inc. | $2.1B | — | — | — | — | — | — | LEAN BEAR | — |
| HNGZY Hangzhou Tigermed Consulting Co., Ltd | $6.9B | 597.8 | 0.5 | 1.6 | -24.2 | 12.0 | 6 | LEAN BEAR | 11.2 |
| SHJBF Shanghai Junshi Biosciences Co., Ltd. | $4.8B | -69.3 | -7.1 | -6.3 | 4.4 | 29.7 | 5 | LEAN BEAR | -20.8 |
| MCVEF Medicover AB (publ) | $4.1B | 44.4 | 16.9 | 6.8 | 3.8 | 9.4 | 7 | LEAN BEAR | 0.0 |
| CLDX Celldex Therapeutics, Inc. | $2.3B | -6.8 | -43.9 | -13685.9 | -334104.5 | -98.1 | 1 | LEAN BEAR | 12.3 |
| PTKFF PT Kalbe Farma Tbk. | $2.0B | 8.9 | 15.4 | 17.6 | 9.1 | 13.2 | 5 | LEAN BEAR | -18.5 |
| RSMDF ResMed Inc. | $36B | 23.9 | 24.3 | 25.3 | 26.2 | 9.9 | 7 | LEAN BEAR | -8.5 |
| OGN Organon & Co. | $3.6B | 17.4 | 24.0 | 6.0 | 6.9 | -2.5 | 5 | LEAN BEAR | 52.4 |
| BTSGU BrightSpring Health Services, Inc. Tangible Equity Unit | $12B | 41.0 | 15.5 | 10.3 | 2.2 | 19.9 | 7 | LEAN BEAR | 70.4 |
| SRRK Scholar Rock Holding Corporation | $5.0B | -12.5 | -167.8 | 931.3 | — | — | 2 | LEAN BEAR | 45.5 |
| ELVN Enliven Therapeutics, Inc. | $3.0B | -25.8 | -15.3 | -6535.0 | — | — | 3 | LEAN BEAR | 101.9 |
| UFPT UFP Technologies, Inc. | $2.3B | 31.2 | 17.1 | 13.3 | 12.0 | 7.3 | 7 | LEAN BEAR | 45.5 |
| GALNF Galenica AG | $5.0B | 27.6 | 11.2 | 6.8 | 3.1 | 6.2 | 4 | BEARISH | 32.2 |
| ELAN Elanco Animal Health Incorporated | $11B | -55.9 | -3.0 | 3.7 | 3.9 | 12.0 | 5 | BEARISH | 5.5 |
| HSIC Henry Schein, Inc. | $9.5B | 24.3 | 12.2 | 8.7 | 2.7 | 6.5 | 7 | BEARISH | 32.9 |
| INDV Indivior Pharmaceuticals Inc | $4.3B | 12.0 | -152.4 | 528.3 | 35.6 | 13.5 | 4 | BEARISH | 36.7 |
| NEO NeoGenomics, Inc. | $2.2B | -42.8 | -6.3 | -4.8 | 1.1 | 11.2 | 5 | BEARISH | 59.7 |
| ARGX argenx SE | $55B | 31.3 | 26.0 | 50.1 | 29.8 | 162.5 | 7 | BEARISH | 7.0 |
| WXIBF WuXi Biologics (Cayman) Inc. | $26B | 31.4 | 10.6 | 16.0 | 20.7 | 16.0 | 9 | BEARISH | 23.1 |
| RYTM Rhythm Pharmaceuticals, Inc. | $6.2B | -29.2 | -200.0 | 144.2 | -69.2 | 53.5 | 4 | BEARISH | -18.0 |
| ACAD Acadia Pharmaceuticals Inc. | $3.4B | 8.9 | 35.7 | 63.9 | 10.2 | 11.8 | 5 | BEARISH | -9.2 |
| PANHF Ping An Healthcare and Technology Company Limited | $2.1B | 20.7 | 4.6 | 5.6 | 8.8 | 2.9 | 6 | BEARISH | -61.7 |
| CLOV Clover Health Investments, Corp. | $2.4B | -113.1 | -5.1 | -8.3 | 3.8 | 54.0 | 4 | BEARISH | 42.5 |
| BAYRY Bayer AG | $48B | -25.8 | -5.5 | 6.4 | 2.0 | -1.5 | 4 | BEARISH | 59.4 |
| INCY Incyte Corporation | $23B | 14.1 | 30.7 | 82.1 | 35.0 | 26.9 | 8 | BEARISH | 26.9 |
| EWTX Edgewise Therapeutics, Inc. | $4.2B | -21.3 | -38.0 | 1912.5 | — | — | 1 | BEARISH | 159.4 |
| ADPT Adaptive Biotechnologies Corporation | $4.1B | -65.1 | -39.6 | -14.1 | -55.6 | 50.1 | 5 | BEARISH | 53.1 |
| RGC Regencell Bioscience Holdings Limited | $3.8B | -283.1 | -128.5 | 1692.4 | — | — | 3 | BEARISH | -57.8 |
| CLCGY Clicks Group Limited | $3.1B | 16.0 | 47.7 | 39.1 | 6.5 | 6.3 | 6 | BEARISH | -37.6 |
| PHVS Pharvaris N.V. | $2.2B | -10.6 | -70.7 | 860.9 | — | — | 4 | BEARISH | 37.1 |
| ALVOW Alvotech | $3.9B | -7.9 | 98.5 | 3.3 | -63.2 | -12.2 | 0 | BEARISH | -84.6 |
| SOLV Solventum Corporation | $15B | 10.1 | 34.0 | 18.1 | 4.2 | -0.9 | 7 | BEARISH | 18.8 |
| SLS SELLAS Life Sciences Group, Inc. | $2.3B | -54.6 | -39.6 | 55646.0 | — | — | 4 | BEARISH | 493.7 |
| TNGX Tango Therapeutics, Inc. | $3.9B | -26.0 | -21.3 | -253.2 | — | 121.5 | 3 | BEARISH | 194.8 |
| NHNKY Nihon Kohden Corporation | $3.1B | 19.1 | 7.8 | 7.9 | -1.6 | 2.6 | 9 | BEARISH | -22.6 |
| GRDN Guardian Pharmacy Services, Inc. | $2.5B | 37.4 | 31.7 | 33.2 | 6.2 | 10.3 | 7 | BEARISH | 39.9 |
| IMNM Immunome, Inc. | $2.1B | -7.1 | -64.0 | -2208.4 | — | -100.0 | 4 | BEARISH | 11.4 |
| PCVX Vaxcyte, Inc. | $9.5B | -7.9 | -36.5 | -66.4 | — | — | 0 | BEARISH | 44.2 |
| BDULF Bangkok Dusit Medical Services Public Company Limited | $9.7B | 20.7 | 15.0 | 12.4 | 12.1 | 1.3 | 4 | BEARISH | -3.2 |
| XENE Xenon Pharmaceuticals Inc. | $3.4B | -7.5 | -43.6 | -109.7 | — | -100.0 | 3 | BEARISH | -13.2 |
| CELC Celcuity Inc. | $3.2B | -15.5 | -1433.7 | 1325.2 | — | — | 3 | BEARISH | -6.8 |
| DYN Dyne Therapeutics, Inc. | $2.9B | -4.9 | -81.6 | 240.4 | — | — | 2 | BEARISH | -4.7 |
| IVBXF Innovent Biologics, Inc. | $20B | 97.0 | 6.9 | 67.2 | 14.5 | 35.4 | 6 | BEARISH | -5.6 |
| RADLY Raia Drogasil S.A. | $7.2B | 21.1 | 19.4 | 16.9 | 3.8 | 10.9 | 7 | BEARISH | -21.9 |
| KNSA Kiniksa Pharmaceuticals International, plc | $6.0B | 59.9 | 14.0 | 51.6 | 10.4 | 58.9 | 7 | BEARISH | 88.2 |
| SHPMY Shanghai Pharmaceuticals Holding Co., Ltd | $5.1B | 12.8 | 6.2 | 6.5 | 2.9 | 4.1 | 5 | BEARISH | -16.3 |
| BMRN BioMarin Pharmaceutical Inc. | $11B | 146.9 | 1.2 | 1.4 | 4.5 | 11.2 | 4 | BEARISH | 2.2 |
| OCPNF Olympus Corporation | $12B | 24.6 | 10.6 | 12.7 | 7.9 | 7.8 | 5 | BEARISH | -9.8 |
| GNNSF Genscript Biotech Corporation | $9.6B | -14.1 | -15.4 | 2.9 | -32.0 | 53.1 | 4 | BEARISH | 97.7 |
| ALNY Alnylam Pharmaceuticals, Inc. | $30B | 37.1 | 100.7 | -152.8 | 12.7 | 95.1 | 6 | BEARISH | -50.9 |
| MIRM Mirum Pharmaceuticals, Inc. | $5.2B | -5.7 | -703.0 | -27.3 | -38.1 | 44.0 | 3 | BEARISH | 20.0 |
| SUPN Supernus Pharmaceuticals, Inc. | $2.4B | -20.9 | -10.5 | -12.6 | -26.6 | 24.9 | 3 | BEARISH | -21.6 |
| MDLN Medline Inc. | $30B | 38.5 | 3.2 | 4.4 | 0.8 | — | 4 | BEARISH | — |
| TWST Twist Bioscience Corporation | $9.2B | -69.7 | -29.6 | -29.2 | -29.6 | 19.2 | 2 | BEARISH | 356.3 |
| LNTH Lantheus Holdings, Inc. | $6.5B | 23.8 | 22.2 | 17.1 | 19.3 | 2.3 | 5 | BEARISH | 76.8 |
| ABCL AbCellera Biologics Inc. | $3.8B | -23.0 | -17.3 | -36.2 | -1368.6 | 101.3 | 4 | BEARISH | 111.6 |
| NHC National HealthCare Corporation | $3.7B | 24.1 | 13.1 | 12.6 | 9.9 | 6.9 | 8 | BEARISH | 83.8 |
| CAMRF Camurus AB | $3.7B | 58.0 | 15.8 | 89.3 | 34.3 | -0.2 | 6 | BEARISH | -10.3 |
| RMYHY Ramsay Health Care Limited | $9.2B | 40.8 | 6.6 | 4.2 | 1.8 | 4.2 | 7 | BEARISH | 85.2 |
| DNTH Dianthus Therapeutics, Inc. | $4.3B | -615.5 | -4.1 | -60.1 | -6598.6 | -60.8 | 3 | BEARISH | 138.4 |
| HYPMY Hypera S.A. | $3.8B | 7.9 | 13.2 | 12.8 | 21.0 | 31.8 | 8 | BEARISH | -7.7 |
| RCUS Arcus Biosciences, Inc. | $2.3B | -4.5 | -89.2 | 309.6 | -222.0 | -55.3 | 0 | BEARISH | 5.8 |
| PRAX Praxis Precision Medicines, Inc. | $7.1B | -20.8 | -38.9 | -51.2 | — | -100.0 | 4 | BEARISH | 50.2 |
| RVMDW Revolution Medicines, Inc. Warrant | $40B | -20.6 | -79.1 | 186.4 | — | — | 1 | BEARISH | 2279.1 |
| BEAM Beam Therapeutics Inc. | $2.5B | -29.1 | -8.1 | -184.5 | -25036.3 | 158.9 | 4 | BEARISH | -15.6 |
| ARWR Arrowhead Pharmaceuticals, Inc. | $8.2B | -26.2 | -64.8 | 65.7 | -258.2 | 12.2 | 4 | BEARISH | 57.9 |
| IMVT Immunovant, Inc. | $5.9B | -10.1 | -80.1 | 707.5 | -2159.6 | — | 2 | BEARISH | 50.3 |
| DNLI Denali Therapeutics Inc. | $2.9B | -6.6 | -54.9 | -281.7 | -3539.2 | — | 3 | BEARISH | 17.5 |
| WUXAY WuXi AppTec Co., Ltd. | $68B | 15.4 | 30.2 | 35.4 | 39.1 | 25.0 | 8 | BEARISH | 85.4 |
| TEM Tempus AI, Inc. | $12B | -48.0 | -67.4 | -19.8 | 1.5 | 50.4 | 4 | BEARISH | -22.8 |
| TXG 10x Genomics, Inc. | $9.3B | -129.7 | -9.4 | -19.8 | -11.9 | -4.3 | 5 | BEARISH | 446.1 |
| BLTE Belite Bio, Inc | $5.9B | -52.1 | -20.8 | -11.5 | — | — | 3 | BEARISH | 55.4 |
| CGON CG Oncology Inc. | $5.5B | -23.3 | -26.4 | -2066.1 | -6832.8 | 1030.3 | 3 | BEARISH | 46.6 |
| RTEZ Rest Ez Inc. | $4.2B | — | — | — | — | — | — | BEARISH | 0.0 |
| AMLX Amylyx Pharmaceuticals, Inc. | $3.4B | -19.4 | -74.7 | 2020.5 | — | 100.0 | 5 | BEARISH | 89.3 |
| INCPF InnoCare Pharma Limited | $2.4B | 18.7 | 12.6 | 45.8 | 23.1 | 108.5 | 4 | BEARISH | -50.9 |
| DMPHF Dermapharm Holding SE | $2.4B | 13.8 | 25.6 | 13.0 | 8.1 | 0.5 | 5 | BEARISH | 20.6 |
| YPHDF Ypsomed Holding AG | $5.7B | 23.8 | 31.1 | 17.4 | 22.5 | -2.3 | 8 | BEARISH | -8.1 |
| VRBCF Virbac S.A. | $3.2B | 18.7 | 13.6 | 12.7 | 11.4 | 3.9 | 5 | BEARISH | 10.8 |
| MEDGF Medacta Group S.A. | $2.7B | 33.1 | 17.1 | 9.8 | 11.4 | 8.9 | 4 | BEARISH | 63.9 |
| ORPEF Emeis | $2.3B | -4.5 | -19.0 | 3.2 | -5.4 | 40.2 | 5 | BEARISH | 0.0 |
| CYTK Cytokinetics, Incorporated | $8.5B | -8.5 | 329.8 | 811.2 | -622.8 | -17.2 | 2 | BEARISH | 5.6 |
| MMED MiniMed Group, Inc. | $5.2B | — | — | — | — | — | — | BEARISH | — |
| VERA Vera Therapeutics, Inc. | $2.0B | -5.0 | -91.8 | 2030.6 | — | — | 1 | BEARISH | 0.3 |
| RVMD Revolution Medicines, Inc. | $40B | -20.6 | -79.1 | 186.4 | — | — | 1 | BEARISH | 243.7 |
| DXCM DexCom, Inc. | $29B | 30.4 | 38.5 | 42.9 | 19.0 | 15.5 | 9 | BEARISH | 10.6 |
| BNTX BioNTech SE | $22B | -11.4 | -9.3 | -18.0 | -777.3 | -8.2 | 2 | BEARISH | -17.1 |
| CORT Corcept Therapeutics Incorporated | $9.3B | 166.5 | 8.1 | 3.1 | 16.5 | 16.0 | 6 | BEARISH | 19.4 |
| KRYS Krystal Biotech, Inc. | $9.2B | 38.2 | 20.1 | 40.4 | 45.9 | 22.6 | 7 | BEARISH | 68.2 |
| HIMS Hims & Hers Health, Inc. | $6.2B | -45.5 | -32.0 | -7.1 | -11.5 | 28.0 | 4 | BEARISH | -43.1 |
| CRSP CRISPR Therapeutics AG | $4.8B | -10.4 | -26.1 | -253.2 | -895.3 | -62.7 | 3 | BEARISH | -27.1 |
| IDYA IDEAYA Biosciences, Inc. | $3.4B | -17.2 | -16.2 | -42.9 | -1269.6 | 3244.7 | 4 | BEARISH | 15.7 |
| TARS Tarsus Pharmaceuticals, Inc. | $3.2B | -64.8 | -13.7 | 268.1 | -10.7 | 105.2 | 5 | BEARISH | 2.5 |
| TLX Telix Pharmaceuticals Limited | $3.1B | 92.5 | 8.6 | -1.0 | 8.0 | 10.5 | 4 | BEARISH | -17.4 |
| MBX MBX Biosciences, Inc. Common Stock | $2.3B | -21.3 | -33.2 | 1634.0 | — | — | 2 | BEARISH | 211.8 |
| PGEN Precigen, Inc. | $2.2B | -5.4 | -4640.4 | -30.1 | 36.5 | 1875.0 | 5 | BEARISH | 42.1 |
| JAZZ Jazz Pharmaceuticals plc | $14B | 13.6 | 22.1 | 26.4 | 16.0 | 12.6 | 8 | BEARISH | 48.9 |
| MDGL Madrigal Pharmaceuticals, Inc. | $10B | -34.2 | -53.3 | -778.9 | -15.9 | 149.0 | 2 | BEARISH | 3.3 |
| IBRX ImmunityBio, Inc. | $8.7B | -8.5 | 122.7 | 33.7 | -449.6 | 192.9 | 4 | BEARISH | 226.8 |
| TVTX Travere Therapeutics, Inc. | $4.7B | -110.7 | -151.8 | -21.0 | -20.5 | 77.1 | 6 | BEARISH | 77.5 |
| HAWPY Haw Par Corporation Limited | $3.0B | 12.3 | 5.2 | 1.6 | 93.0 | -12.8 | 4 | BEARISH | -20.4 |
| CHSYF China Medical System Holdings Limited | $2.7B | 13.6 | 8.6 | 9.0 | 21.9 | 9.2 | 4 | BEARISH | -17.8 |
| BRCTF BioArctic AB | $2.6B | 260.2 | 5.2 | 77.4 | -4.5 | -46.1 | 3 | BEARISH | -8.6 |
| HRMY Harmony Biosciences Holdings, Inc. | $2.1B | 11.9 | 20.5 | 35.7 | 28.9 | 24.3 | 5 | BEARISH | 24.4 |
| INSM Insmed Incorporated | $20B | -23.1 | -87.2 | -364.8 | -3.1 | 185.8 | 5 | BEARISH | -41.7 |
| GIKLY Grifols, S.A. | $15B | 15.9 | 8.4 | 7.4 | 8.2 | -0.2 | 6 | BEARISH | -19.0 |
| IONS Ionis Pharmaceuticals, Inc. | $7.1B | -12.5 | -105.4 | -58.5 | -42.8 | -7.4 | 3 | BEARISH | -39.3 |
| REGMF RemeGen Co., Ltd. | $5.6B | 9.1 | 108.3 | 139.6 | 83.4 | 283.6 | 7 | BEARISH | -16.4 |
| PTCT PTC Therapeutics, Inc. | $5.1B | -124.3 | 20.6 | -5.4 | 23.2 | -42.8 | 2 | BEARISH | -8.6 |
| LABFF Laboratorios Farmaceuticos Rovi, S.A. | $3.4B | 17.0 | 29.3 | 19.6 | 39.1 | 3.3 | 6 | BEARISH | -25.9 |
| PBLS Parabilis Medicines, Inc. | $3.0B | — | — | — | — | — | — | BEARISH | — |
| AMFPF Amplifon S.p.A. | $3.0B | 42.9 | 5.7 | 7.2 | 6.4 | -0.2 | 5 | BEARISH | -36.3 |
| BKD Brookdale Senior Living Inc. | $2.4B | -16.5 | -362.1 | 10.3 | 3.2 | -2.3 | 6 | BEARISH | 11.9 |
| NAMS NewAmsterdam Pharma Company N.V. | $2.3B | -9.1 | -36.8 | 8216.2 | -1732.9 | -88.9 | 2 | BEARISH | -46.2 |
| SMMT Summit Therapeutics Inc. | $12B | -13.2 | -192.5 | 1714.4 | — | — | 3 | BEARISH | -22.7 |
| SBMFF Sino Biopharmaceutical Limited | $12B | 30.4 | 21.1 | 40.0 | 17.7 | 28.2 | 7 | BEARISH | -28.2 |
| AXSM Axsome Therapeutics, Inc. | $7.6B | -38.5 | -245.1 | 859.1 | -23.5 | 56.9 | 5 | BEARISH | 13.4 |
| SFOSF Shanghai Fosun Pharmaceutical (Group) Co., Ltd. | $5.8B | 17.8 | 10.7 | 6.3 | 8.4 | 53.9 | 7 | BEARISH | -34.2 |
| TRSBF 3SBio Inc. | $4.3B | 3.4 | 37.1 | 80.3 | 25.3 | 93.8 | 7 | BEARISH | -48.7 |
| VKTX Viking Therapeutics, Inc. | $3.1B | -5.3 | -88.9 | 495.6 | — | — | 1 | BEARISH | -28.6 |
| TMDX TransMedics Group, Inc. | $2.5B | 15.9 | 36.3 | 18.7 | 7.7 | 25.8 | 3 | BEARISH | -45.2 |
| ZLDPF Zealand Pharma A/S | $2.4B | 5.7 | 16.3 | 57.2 | 87.2 | -49.2 | 3 | BEARISH | -54.1 |
Profile Radar
Valuation vs Profitability
Performance Comparison
Industry Market Share
HQY vs Benchmarks
ROIC
Gross Margin
Op Margin
Net Margin
Revenue Growth
P/E Ratio
ROE
Piotroski F